The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
RNA-Based Therapeutics and Vaccines-Global Market Insights and Sales Trends 2024
Synopsis
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The global RNA-Based Therapeutics and Vaccines market size is expected to reach US$ 634.8 million by 2029, growing at a CAGR of 57.3% from 2023 to 2029. The market is mainly driven by the significant applications of RNA-Based Therapeutics and Vaccines in various end use industries. The expanding demands from the Oncology, Immunology, Ophthalmology and Cardiovascular Diseases, are propelling RNA-Based Therapeutics and Vaccines market. RNA-Based Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the RNA-Based Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global RNA-Based Therapeutics and Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global RNA-Based Therapeutics and Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, RNA-Based Therapeutics and Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of RNA-Based Therapeutics and Vaccines covered in this report include Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech and MiRagen Therapeutics, etc.
The global RNA-Based Therapeutics and Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Global RNA-Based Therapeutics and Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global RNA-Based Therapeutics and Vaccines market, Segment by Type:
RNA-Based Therapeutics
RNA-Based Vaccines
Global RNA-Based Therapeutics and Vaccines market, by Application
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of RNA-Based Therapeutics and Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The global RNA-Based Therapeutics and Vaccines market size is expected to reach US$ 634.8 million by 2029, growing at a CAGR of 57.3% from 2023 to 2029. The market is mainly driven by the significant applications of RNA-Based Therapeutics and Vaccines in various end use industries. The expanding demands from the Oncology, Immunology, Ophthalmology and Cardiovascular Diseases, are propelling RNA-Based Therapeutics and Vaccines market. RNA-Based Therapeutics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the RNA-Based Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global RNA-Based Therapeutics and Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global RNA-Based Therapeutics and Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, RNA-Based Therapeutics and Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of RNA-Based Therapeutics and Vaccines covered in this report include Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech and MiRagen Therapeutics, etc.
The global RNA-Based Therapeutics and Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Global RNA-Based Therapeutics and Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global RNA-Based Therapeutics and Vaccines market, Segment by Type:
RNA-Based Therapeutics
RNA-Based Vaccines
Global RNA-Based Therapeutics and Vaccines market, by Application
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of RNA-Based Therapeutics and Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of RNA-Based Therapeutics and Vaccines
1.1 RNA-Based Therapeutics and Vaccines Market Overview
1.1.1 RNA-Based Therapeutics and Vaccines Product Scope
1.1.2 RNA-Based Therapeutics and Vaccines Market Status and Outlook
1.2 Global RNA-Based Therapeutics and Vaccines Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global RNA-Based Therapeutics and Vaccines Market Size by Region (2018-2029)
1.4 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Region (2018-2023)
1.5 Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2024-2029)
1.6 Key Regions, RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
1.6.1 North America RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
1.6.2 Europe RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
1.6.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
1.6.4 Latin America RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
1.6.5 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size (2018-2029)
2 RNA-Based Therapeutics and Vaccines Market by Type
2.1 Introduction
2.1.1 RNA-Based Therapeutics
2.1.2 RNA-Based Vaccines
2.2 Global RNA-Based Therapeutics and Vaccines Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Type (2018-2023)
2.2.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America RNA-Based Therapeutics and Vaccines Revenue Breakdown by Type (2018-2029)
2.3.2 Europe RNA-Based Therapeutics and Vaccines Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America RNA-Based Therapeutics and Vaccines Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue Breakdown by Type (2018-2029)
3 RNA-Based Therapeutics and Vaccines Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Immunology
3.1.3 Ophthalmology
3.1.4 Cardiovascular Diseases
3.1.5 Infectious Diseases
3.1.6 Genetic Diseases
3.1.7 Others
3.2 Global RNA-Based Therapeutics and Vaccines Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Application (2018-2023)
3.2.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America RNA-Based Therapeutics and Vaccines Revenue Breakdown by Application (2018-2029)
3.3.2 Europe RNA-Based Therapeutics and Vaccines Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America RNA-Based Therapeutics and Vaccines Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue Breakdown by Application (2018-2029)
4 RNA-Based Therapeutics and Vaccines Competition Analysis by Players
4.1 Global RNA-Based Therapeutics and Vaccines Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2022)
4.3 Date of Key Players Enter into RNA-Based Therapeutics and Vaccines Market
4.4 Global Top Players RNA-Based Therapeutics and Vaccines Headquarters and Area Served
4.5 Key Players RNA-Based Therapeutics and Vaccines Product Solution and Service
4.6 Competitive Status
4.6.1 RNA-Based Therapeutics and Vaccines Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Alnylam Pharmaceuticals
5.1.1 Alnylam Pharmaceuticals Profile
5.1.2 Alnylam Pharmaceuticals Main Business
5.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.1.4 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.1.5 Alnylam Pharmaceuticals Recent Developments
5.2 Arbutus Biopharma
5.2.1 Arbutus Biopharma Profile
5.2.2 Arbutus Biopharma Main Business
5.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.2.4 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.2.5 Arbutus Biopharma Recent Developments
5.3 Arrowhead Pharmaceuticals
5.3.1 Arrowhead Pharmaceuticals Profile
5.3.2 Arrowhead Pharmaceuticals Main Business
5.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.3.4 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.3.5 BioNTech Recent Developments
5.4 BioNTech
5.4.1 BioNTech Profile
5.4.2 BioNTech Main Business
5.4.3 BioNTech RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.4.4 BioNTech RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.4.5 BioNTech Recent Developments
5.5 CureVac
5.5.1 CureVac Profile
5.5.2 CureVac Main Business
5.5.3 CureVac RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.5.4 CureVac RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.5.5 CureVac Recent Developments
5.6 Dicerna Pharmaceuticals
5.6.1 Dicerna Pharmaceuticals Profile
5.6.2 Dicerna Pharmaceuticals Main Business
5.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.6.4 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.6.5 Dicerna Pharmaceuticals Recent Developments
5.7 Regulus Therapeutics
5.7.1 Regulus Therapeutics Profile
5.7.2 Regulus Therapeutics Main Business
5.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.7.4 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.7.5 Regulus Therapeutics Recent Developments
5.8 Marina Biotech
5.8.1 Marina Biotech Profile
5.8.2 Marina Biotech Main Business
5.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.8.4 Marina Biotech RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.8.5 Marina Biotech Recent Developments
5.9 MiRagen Therapeutics
5.9.1 MiRagen Therapeutics Profile
5.9.2 MiRagen Therapeutics Main Business
5.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.9.4 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.9.5 MiRagen Therapeutics Recent Developments
5.10 Moderna Therapeutics
5.10.1 Moderna Therapeutics Profile
5.10.2 Moderna Therapeutics Main Business
5.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.10.4 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.10.5 Moderna Therapeutics Recent Developments
5.11 Quark Pharmaceuticals
5.11.1 Quark Pharmaceuticals Profile
5.11.2 Quark Pharmaceuticals Main Business
5.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.11.4 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.11.5 Quark Pharmaceuticals Recent Developments
5.12 Roche
5.12.1 Roche Profile
5.12.2 Roche Main Business
5.12.3 Roche RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.12.4 Roche RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.12.5 Roche Recent Developments
5.13 Sylentis
5.13.1 Sylentis Profile
5.13.2 Sylentis Main Business
5.13.3 Sylentis RNA-Based Therapeutics and Vaccines Products, Services and Solutions
5.13.4 Sylentis RNA-Based Therapeutics and Vaccines Revenue (US$ Million) & (2018-2023)
5.13.5 Sylentis Recent Developments
6 North America
6.1 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 RNA-Based Therapeutics and Vaccines Market Dynamics
11.1 RNA-Based Therapeutics and Vaccines Industry Trends
11.2 RNA-Based Therapeutics and Vaccines Market Drivers
11.3 RNA-Based Therapeutics and Vaccines Market Challenges
11.4 RNA-Based Therapeutics and Vaccines Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
